SARS-CoV-2-Neutralizing Monoclonal COVID-19 Antibody DZIF-10c by Inhalation
Status:
Completed
Trial end date:
2021-09-23
Target enrollment:
Participant gender:
Summary
This is the first-in-human phase 1/2a trial of the inhaled administration of the
SARS-CoV-2-neutralizing monoclonal antibody DZIF-10c in healthy volunteers and
SARS-CoV-2-infected individuals. It will evaluate the safety, pharmacokinetic profile,
immunogenicity, and antiviral activity of DZIF-10c.